MSN: Who created the polio vaccine?
New generation discovering UC virologist Albert Sabin's work — the polio vaccine
The COVID-19 era is casting light back more than a half century to the time when former University of Cincinnati virologist Albert Sabin developed the live oral polio vaccine. Recent worldwide media coverage, including the latest from MSN, is highlighting the health care hero's work.
"By 1963, Sabin had created an oral live-virus vaccine for all three types of poliovirus that was approved for use by the U.S. government," states the MSN story. "Sabin's version was cheaper and easier to produce than the Salk vaccine, and it quickly supplanted the Salk vaccine in the U.S."
In 1972, Sabin donated his vaccine strains to the World Health Organization (WHO), which greatly increased the vaccine's availability in low-income countries.
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Stay up on all UC's COVID-19 stories, read more #UCtheGood content, or take a UC virtual visit and begin picturing yourself at an institution that inspires incredible stories.
Related Stories
Is a colonoscopy painful?
May 13, 2026
The University of Cincinnati's Susan Kais, MD, assistant professor of clinical medicine in the Division of Gastroenterology and Hepatology in the College of Medicine and UC Health gastroenterologist, recently appeared on the ARC Cincinnati morning program on Local 12/WKRC-TV to answer common questions from viewers about colonoscopies and to dispel myths.
Telescope captures information about lonely Jupiter-like gas giant
May 13, 2026
Science outlets highlight a University of Cincinnati student's collaborative discoveries about an exoplanet 901 light years away.
UC achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy
May 13, 2026
Researchers at the University of Cincinnati Gardner Neuroscience Institute’s Brain Tumor Center have been confirmed as the first in the world to achieve complete remission of a rare pituitary cancer using a novel immunotherapy treatment. The findings were published in Surgical Neurology International and recently featured in The Cancer Letter.